Emerging biological therapies in primary Sjögren's syndrome

M Ramos-Casals, P Brito-Zerón - Rheumatology, 2007 - academic.oup.com
Sjögren's syndrome (SS) is a systemic autoimmune disease that mainly affects the exocrine
glands and usually presents as persistent dryness of the mouth and eyes. SS primarily …

Biologic treatment in Sjögren's syndrome

PR Sada, D Isenberg, C Ciurtin - Rheumatology, 2015 - academic.oup.com
SS is a chronic systemic autoimmune disease characterized by decreased exocrine gland
function. A variety of other disease manifestations may also be present, including general …

An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development

S Retamozo, A Sisó-Almirall… - Expert Opinion on …, 2021 - Taylor & Francis
ABSTRACT Introduction: Primary Sjögren syndrome (pSS) is a systemic autoimmune
disease that may affect 3 in 1,000 people within the general population. The therapeutic …

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: a systematic review of trials

R Felten, F Scher, J Sibilia, JE Gottenberg… - Autoimmunity Reviews, 2019 - Elsevier
To date, no immunomodulatory drug has proved efficacious in primary Sjögren's syndrome
(pSS). In pSS, difficulties in drug efficacy assessment is related to the large spectrum of …

Present and future of biologic drugs in primary Sjögren's syndrome

D Sambataro, G Sambataro, Y Dal Bosco… - Expert Opinion on …, 2017 - Taylor & Francis
ABSTRACT Introduction: Primary Sjögren's (pSS) syndrome is a chronic, autoimmune, and
systemic disease characterized by xerostomia, xerophthalmia, muscle pain and fatigue. The …

Treating the underlying pathophysiology of primary Sjögren syndrome: recent advances and future prospects

P Brito-Zerón, S Retamozo, H Gheitasi… - Drugs, 2016 - Springer
Sjögren Syndrome (SS) is a systemic autoimmune disease with a wide clinical spectrum that
extends from sicca symptoms of the mucosal surfaces to extra-glandular systemic …

[PDF][PDF] Limited efficacy of targeted treatments in Sjögren's syndrome: why

AG Tzioufas, AV Goules - Clin Exp Rheumatol, 2018 - clinexprheumatol.org
Limited efficacy of targeted treatments in SS io fas o es the disease is advanced (2, 8).
Therefore, it is rational to assume that the expected therapeutic window has been narrowed …

Use of biologics in Sjögren's syndrome

G Nocturne, D Cornec, R Seror… - Rheumatic Disease …, 2016 - rheumatic.theclinics.com
The management of patients with primary Sjogren syndrome (pSS) has long suffered from
the lack of effective treatments. Progress made in the understanding of pSS pathogenesis …

Emerging drugs for primary Sjögren's syndrome

S Gandolfo, S De Vita - Expert Opinion on Emerging Drugs, 2019 - Taylor & Francis
ABSTRACT Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune systemic
disease characterized by a complex and not yet completely elucidated etiopathogenesis …

Treatment of primary Sjögren syndrome

A Saraux, JO Pers… - Nature Reviews …, 2016 - nature.com
Primary Sjögren syndrome (pSS) is a progressive autoimmune disease characterized by
sicca and systemic manifestations. In this Review, we summarize the available data on …